Current, new and novel therapy for castration-resistant prostate cancer.

about

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.

P2860

Q38895320-EFCF405F-A823-4E2A-A722-8C280FC518AC

P2860

Current, new and novel therapy for castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q38123202

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current, new and novel therapy for castration-resistant prostate cancer.

@en

type

Item

label

Current, new and novel therapy for castration-resistant prostate cancer.

@en

prefLabel

Current, new and novel therapy for castration-resistant prostate cancer.

@en

P1476

Current, new and novel therapy for castration-resistant prostate cancer

@en

P2093

Dominique Prapotnich

http://www.w3.org/2001/XMLSchema#string

Eric Barret

http://www.w3.org/2001/XMLSchema#string

Francois Rozet

http://www.w3.org/2001/XMLSchema#string

Jennifer Cerruti

http://www.w3.org/2001/XMLSchema#string

Josep M Gaya

http://www.w3.org/2001/XMLSchema#string

Marc Galiano

http://www.w3.org/2001/XMLSchema#string

Matthieu Durand

http://www.w3.org/2001/XMLSchema#string

Mostefa Bennamoun

http://www.w3.org/2001/XMLSchema#string

Peter Macek

http://www.w3.org/2001/XMLSchema#string

Rafael Sanchez-Salas

http://www.w3.org/2001/XMLSchema#string

P2860

Src family kinases in tumor progression and metastasis

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Cancer statistics, 2008

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

P304

819-827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2013.811154

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Youness Ahallal

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23875660

http://www.w3.org/2001/XMLSchema#string

Current, new and novel therapy for castration-resistant prostate cancer.

about

P2860

P2860

Current, new and novel therapy for castration-resistant prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698